Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Cobalt protoporphyrin (CoPP) improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 8/June/2015, 07.27 am

Vitamin-based therapy for Hyperglycemia & T2DM: Vitamin-E (Tocopherol) increases the expression of AMPK (5′ adenosine monophosphate-activated protein kinase), decreases gluconeogenesis and fasting glucose level via up regulation of its target gene, 8/June/2015, 6.56 am
June 8, 2015
Small molecule-based therapy for Alzheimer’s disease: NF-κBp65 ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene, 8/June/2014, 7.56 am
June 8, 2015
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Cobalt protoporphyrin (CoPP) improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10).

Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were: (i) due to ischemic heart disease; and (ii) expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.

This study suggests, for the first time, a small molecule-based cardiac regeneration therapy. Cobalt protoporphyrin, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardimyocyte survival/regeneration. By treating myocardial patients with Cobalt protoporphyrin, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Thus, pharmacological formulations encompassing Cobalt protoporphyrin or its analogues” may be used to improve cardiac function after myocardial infarction.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Cobalt protoporphyrin (CoPP) improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 8/June/2015,  07.27 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How Cobalt protoporphyrin (CoPP) increases the expression of PNUTS/PPP1R10

Comments are closed.